Jamma Li
Royal North Shore Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jamma Li.
Pharmacogenomics | 2016
Dinh Van Nguyen; Christopher Vidal; Jamma Li; Richard B. Fulton; Suran L. Fernando
AIM In prevention of allopurinol and abacavir hypersensitivity, screening HLA-B*58:01/57:01 has been highly recommended prior to commencing these therapies. Therefore, we aimed at developing and validating a rapid and robust screening method for HLA-B*58:01/57:01. MATERIALS & METHODS Real-time polymerase chain reaction with TaqMan probes was employed to detect HLA-B*58:01/57:01. RESULTS The newly developed assay has the sensitivity of 100% (95% CI: 79.4-100.0%), the specificity of 98.8% (95% CI: 93.6-99.9%), the positive predictive value of 94.1% (95% CI: 71.3-99.9%) and the negative predictive value of 100.0% (95% CI: 95.7-100.0%). The lowest limit of detection is 0.04 ng/µl of DNA. CONCLUSION The present method is a rapid and robust assay that is appropriate for screening of HLA-B*58:01/*57:01 alleles.
Human Immunology | 2016
Dinh Van Nguyen; Christopher Vidal; Hieu Chi Chu; Nga Thi Quynh Do; Tu Thi Linh Tran; Huong Thi Minh Le; Richard B. Fulton; Jamma Li; Suran L. Fernando
OBJECTIVES Screening for the HLA-B*15:02 allele has been recommended to prevent carbamazepine (CBZ) - induced Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in individuals with Asian ancestry. We aimed, therefore, to develop and validate a robust and inexpensive method for detection of the HLA-B*15:02 allele. METHODS Real-time PCR using TaqMan® probes followed by SYBR® Green was used to detect the HLA-B*15:02 allele prior to treatment with CBZ therapy. RESULTS A total of 121 samples were tested. The assay has a sensitivity of 100% (95% CI: 76.84-100.0%), a specificity of 100% (95% CI: 96.61-100%), a positive predictive value of 100% (95% CI: 76.84-100%) and a negative predictive value of 100.0% (95% CI: 96.61-100.0%), respectively. There was 100% agreement between our results and genotyping using Luminex SSO/SBT/SSP. The lowest limit of detection of the TaqMan® probe is 0.05ng/μl and the SYBR® Green is 0.5ng/μl of DNA. The unit cost of using the TaqMan® probe followed by SYBR® Green is only
Drug Metabolism and Pharmacokinetics | 2016
Christopher Vidal; Jamma Li; Richard B. Fulton; Suran L. Fernando
4.7 USD. CONCLUSION We developed a novel assay for the detection of the HLA-B*15:02 allele, which is robust, inexpensive and suitable for screening individuals of Asian ancestry in the prevention of CBZ-induced SJS/TEN.
Journal of Clinical Neuroscience | 2015
Patrick Aouad; Jamma Li; Christopher Arthur; Richard K. Burt; Suran L. Fernando; John Parratt
Association exists between HLA-B*58:01 allele and allopurinol Stevens-Johnson syndrome (SJS), especially those of an Asian heritage but associations have been also described in Caucasian populations. This creates the need to develop a rapid, robust and inexpensive assay for pre-screening of HLA-B*58:01. A polymorphism within PSORS1C1 gene was recently found in linkage disequilibrium (LD) with HLA-B*58:01 allele in the Japanese population. The aim of this study is to confirm whether this polymorphism can be used as a surrogate biomarker to identify carriers for HLA-B*58:01. No linkage was found between the two in the Australian cohort.
Internal Medicine Journal | 2014
Jamma Li; Suran L. Fernando; Geoffrey K. Herkes
We report a 47-year-old woman with highly active neuromyelitis optica (NMO) and persistent high titre anti-aquaporin-4 antibodies (anti-AQP-4) who was resistant to multiple immune therapies until she underwent autologous hematopoietic stem cell transplant (auto-HSCT). NMO is the only demyelinating disease with a clinically useful serum biomarker, aquaporin-4, a water channel protein expressed on astrocytes. Anti-AQP-4 antibodies correlate with NMO disease activity and animal models strongly suggest the antibody is pathogenic. Auto-HSCT was associated with clinical and radiological remission, improved disability and resolution of AQP-4 antibodies which are still undetectable 12 months later. The utility of auto-HSCT for refractory NMO warrants further investigation, particularly with regards to pre-conditioning regimens and the utility of AQP-4 antibodies as a biomarker for immunological and clinical remission.
HLA | 2017
Dinh Van Nguyen; Christopher Vidal; H. C. Chi; Nga Thi Quynh Do; Richard B. Fulton; Jamma Li; Suran L. Fernando
Behçet disease is a multisystem vasculitis characterised by recurrent oral ulceration in conjunction with other manifestations. Neurological involvement or neuro‐Behçet disease is not common, but typically affects young men at its onset between the ages of 20 and 40 with significant long‐term morbidity and mortality. There is substantial case literature to support the use of tumour necrosis factor antagonists, notably infliximab, in the treatment of neuro‐Behçet disease.
Allergy, Asthma and Immunology Research | 2017
Dinh Van Nguyen; Christopher Vida; Hieu Chi Chu; Richard B. Fulton; Jamma Li; Suran L. Fernando
HLA‐A*31:01 and HLA‐B*15:02 have been widely reported to confer genetic susceptibility to carbamazepine (CBZ)‐induced severe cutaneous adverse reactions (SCARs). Accordingly, the screening for these alleles has been highly recommended to prevent SCAR prior to introducing CBZ therapy. Although a number of methods are available for screening of HLA‐A*31:01 or HLA‐B*15:02 alleles separately, developing an assay that can detect both these alleles would be more clinically practical, cost‐effective and less time‐consuming. Therefore, in this study, a multiplex polymerase chain reaction (PCR) using TaqMan Probe was designed and validated to be able to detect HLA‐A*31:01 and HLA‐B*15:02. In comparison with Luminex‐SSO/SBT/SSB, the multiplex PCR assay for detection of HLA‐A*31:01 and HLA‐B*15:02 had a perfect agreement in the validation group of 125 samples. The method was able to detect the target genes at the DNA concentration of 0.037 ng/μL. The unit cost of this assay is less than
Pathology | 2016
Christopher Vidal; Dinh Van Nguyen; Jamma Li; Fen Cai; Richard B. Fulton; Hieu Chi Chu; Anne Proos; Suran L. Fernando
5 USD with total time of 110 minutes.
Pathology | 2016
Jamma Li; Oliver Giles Best; Stephen P. Mulligan; Suran L. Fernando
The HLA B*58:01 allele has been worldwide reported as a pharmacogenetic susceptibility to allopurinol-induced severe cutaneous adverse reactions (SCARs). To prevent these life-threatening conditions, the American College of Rheumatology hingly recommended that the HLA-B*58:01 be screened prior to the initiation of allopurinol therapy. Therefore, we developed a rapid, robust, inexpensive screening method using SYBR® Green real time PCR to detect the HLA-B*58:01 allele. A total of 119 samples were tested. The assay has a sensitivity of 100% (95% CI: 69.15%-100%), a specificity of 100% (95% CI: 96.67%-100%), a positive predictive value of 100% (95% CI: 69.15%-100%) and a negative predictive value of 100% (95% CI: 96.67%-100%). HLA-B*58:01 genotyping results showed 100% agreement with those obtained from Luminex SSO/SBT/SSP. The lowest limit of detection of this method is 0.8 ng/µL of DNA. The unit cost of the test is only
Leukemia & Lymphoma | 2016
Jamma Li; Oliver Giles Best; Stephen P. Mulligan; Suran L. Fernando
3.8 USD. This novel screening test using SYBR® real time PCR would be appropriate to identify individuals with the HLA-B*58:01 allele for the prevention of allopurinol-induced SCARs.